Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease
Indian Journal of Ophthalmology · 2025
DOI: 10.4103/ijo.ijo_23_24 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Ophthalmology, 2025. Verfasst von Namrata Sharma und 11 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Ophthalmic Solutions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Purpose
To compare the efficacy, safety, and tolerability of lifitegrast 5% versus carboxymethylcellulose (CMC) 0.5% in adult patients with dry eye disease (DED).
Methods
A total of 370 eligible patients with DED were randomized equally to receive twice-daily doses of a single drop in each eye of either lifitegrast 5% or CMC 0.5% for 12 weeks. Follow-up at weeks 2, 6, and 12 evaluated changes from baseline in primary [eye dryness score (EDS), ocular discomfort score (ODS), ocular surface disease index (OSDI), and tear film break-up time (TFBUT)] and secondary [Schirmer tear test (STT) score and corneal fluorescein staining (CFS) score] endpoints. Global improvement, safety, and tolerability were also assessed.
Results
At week 2, values of ocular discomfort score, OSDI, and conjunctival redness were significantly more favorable in patients treated with lifitegrast compared to CMC. At week 6, values of all study variables were better in patients treated with lifitegrast compared to CMC; differences between the groups were statistically significant for all except photophobia. This trend was also maintained at week 12. Global improvement and tolerability were found to be better with lifitegrast than with CMC. No serious safety concerns were reported in any treatment group.
Conclusion
To our knowledge, this is the first active-controlled trial informing on the efficacy, safety, and tolerability of lifitegrast 5%. Significantly more favorable values for EDS (except photophobia), ODS, OSDI, TFBUT, STT score, CFS score, and conjunctival redness score were achieved at week 12 with lifitegrast 5% compared to CMC 0.5%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- All India Institute of Medical Sciences, New Delhi, India.
- LV Prasad Eye Institute, Hyderabad, Telangana, India.
- Narayana Nethralaya, Bangalore, Karnataka, India.
- King George's Medical University, Lucknow, Uttar Pradesh, India.
- Regional Institute of Ophthalmology, Kolkata, West Bengal, India.
- Government Medical College and Government General Hospital, (Old RIMS), Srikakulam, Andhra Pradesh, India.
Zitieren
APA
Sharma, N., Basu, S., Shetty, R., Kumar, P., Mondal, A., Babu, P. S., Srivastava, R., Pande, R. A., Karat, S., Desai, H. P., Manjula, S., & Kumar, M. K. (2025). Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_23_24
Vancouver
Sharma N, Basu S, Shetty R, Kumar P, Mondal A, Babu PS, et al. Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease. Indian Journal of Ophthalmology. 2025. doi:10.4103/ijo.ijo_23_24
BibTeX
@article{Sharma2025,
author = {Sharma, Namrata and Basu, Sayan and Shetty, Rohit and Kumar, Pramod and Mondal, Anindita and Babu, P Seshu and Srivastava, Richa and Pande, Ranjana A and Karat, Shubashree and Desai, Hemaxi P and Manjula, S and Kumar, M Krishna},
title = {Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease},
journal = {Indian Journal of Ophthalmology},
year = {2025},
doi = {10.4103/ijo.ijo_23_24}
}
EUVIMED